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SMAD6 variants in craniosynostosis: genotype and
phenotype evaluation
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Purpose: Enrichment of heterozygous missense and truncating
SMAD6 variants was previously reported in nonsyndromic sagittal
and metopic synostosis, and interaction of SMAD6 variants with a
common polymorphism near BMP2 (rs1884302) was proposed to
contribute to inconsistent penetrance. We determined the occur-
rence of SMAD6 variants in all types of craniosynostosis, evaluated
the impact of different missense variants on SMAD6 function, and
tested independently whether rs1884302 genotype significantly
modifies the phenotype.
Methods:We performed resequencing of SMAD6 in 795 unsolved
patients with any type of craniosynostosis and genotyped rs1884302
in SMAD6-positive individuals and relatives. We examined the
inhibitory activity and stability of SMAD6 missense variants.
Results: We found 18 (2.3%) different rare damaging SMAD6
variants, with the highest prevalence in metopic synostosis (5.8%)
and an 18.3-fold enrichment of loss-of-function variants compared-
with gnomAD data (P < 10−7). Combined with eight additional
variants, ≥20/26 were transmitted from an unaffected parent but
rs1884302 genotype did not predict phenotype.
Conclusion: Pathogenic SMAD6 variants substantially increase the
risk of both nonsyndromic and syndromic presentations of
craniosynostosis, especially metopic synostosis. Functional analysis is
important to evaluate missense variants. Genotyping of rs1884302 is
not clinically useful. Mechanisms to explain the remarkable diversity
of phenotypes associated with SMAD6 variants remain obscure.
Genetics in Medicine (2020) https://doi.org/10.1038/s41436-020-0817-2
Keywords: BMP2; metopic synostosis; digenic inheritance; two-
locus; protein instability
INTRODUCTION
Craniosynostosis (CRS), the premature fusion of the cranial
sutures, is a heterogeneous disorder with a prevalence of ∼1 in
2000. Environmental factors, polygenic inheritance and single-
gene or chromosomal abnormalities all contribute to its
complex manifestations. Variants in >60 genes have been
identified as recurrently associated with CRS, with an under-
lying genetic cause being found in ∼24% of patients overall.1–3
The proportion in whom a cause can be determined varies
widely depending on clinical diagnosis: from 88% for bicoronal
synostosis down to 8% for sagittal synostosis (SS).2 Until
recently, success in identifying a genetic diagnosis has been
particularly low in nonsyndromic midline CRS, under 1% for
both sagittal and metopic suture fusions.2
In 2016, Timberlake et al.4 performed exome sequencing of
132 parent–offspring trios and 59 additional probands
presenting with clinically nonsyndromic SS, metopic (MS),
or combined metopic/sagittal synostosis, seeking evidence for
major monogenic contributions to these disorders. Based on
enrichment of de novo variants and inherited damaging
variants, this study identified a single significant gene,
SMAD6, located at 15q22.3.4
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SMAD6, originally identified in mammals by homology-
based cloning,5,6 encodes one of two (with SMAD7)
inhibitory members of the SMAD family required for
regulated intracellular signal transduction by members of
the transforming growth factor β/bone morphogenetic
protein (TGFβ/BMP) superfamily.7–9 Intriguingly, enrich-
ment of rare SMAD6 variants has also been reported in
association with several other distinct phenotypes, namely
congenital heart disease,10–12 bicuspid aortic valve (BAV) and
ascending thoracic aortic aneurysm (TAA),13–15 intellectual
disability,16 and radioulnar synostosis.17
In a follow-up study, Timberlake et al. increased the sample
size of probands with midline CRS and no other genetic
diagnosis to 379 (45 pedigrees included ≥1 additional affected
family member).18 They found damaging SMAD6 variants in
4/234 (1.7%) SS, 11/135 (8.1%) MS, and 2/10 (20%) combined
metopic/sagittal synostosis probands. Although de novo
variants (DNMs) were identified in four families, in the
remainder, the SMAD6 variant was transmitted by an
apparently unaffected (i.e., nonpenetrant) parent. Similar
observations of nonpenetrance of SMAD6 variants were made
for several of the other described disease associations.13,14,17
To seek an explanation for the unpredictable penetrance,
Timberlake et al.4,18 genotyped a single-nucleotide poly-
morphism (SNP), rs1884302, previously reported in a
genome-wide association study (GWAS) of nonsyndromic
SS to be the most significant associated SNP, which may
differentially regulate the most proximal gene BMP2.19,20 The
risk-conferring C allele (prevalence in non-Finnish Europeans
of 32.7%, gnomAD),21 was found to be present in 15/21
individuals with CRS but only 1/20 unaffected relatives
heterozygous for the SMAD6 variant but without CRS,
suggesting a two-locus mechanism to account for variable
manifestation of CRS.18
Although the studies described above4,18 represent an
important advance in delineating the contribution of single-
gene variants to nonsyndromic midline CRS, they raise
several questions. First, what is the contribution of SMAD6
variants in all presentations of CRS (including syndromic
diagnoses and fusion of coronal or lambdoid sutures)?
Second, can it be assumed that all rare SMAD6 missense
variants affect protein function? Third, can the two-locus
(SMAD6/rs1884302) model be confirmed in an independent
cohort? Here, we address these questions. We confirm the
primary finding that SMAD6 variants are enriched in CRS,
especially metopic synostosis, but find a more diverse pattern
of clinical presentation; in addition, we illustrate the
importance of combining functional studies with frequency-
based evaluation of variants to refine likelihood of patho-
genicity. Finally, we report that the two-locus model does not
account for inconsistencies of penetrance of damaging
SMAD6 variants in our data set.
MATERIALS AND METHODS
Patients
The clinical studies were approved by respective Institutional
Review Boards (IRB): Oxfordshire Research Ethics Committee
(REC) B (C02.143), London–Riverside REC (09/H0706/20),
East of England–Cambridge South REC (14/EE/1112 for
100,000 Genomes Project [100kGP]), the Medical Ethical
Committee of the Erasmus University Medical Center
Rotterdam (MEC-2012–140), and the IRB of the University
of California–Davis (International Craniosynostosis Consor-
tium [ICC]; protocol 215635–23). Written informed consent
to obtain samples for genetics research was given by each
child’s parent or guardian. Written authorization for
publication of clinical photographs was obtained from every
individual and/or their parent/guardian. The clinical diag-
nosis of CRS was confirmed by three-dimensional computed
tomography scanning of the skull; routine genetic investiga-
tions are described in Supplementary Information. Patients
were considered to have a syndromic diagnosis if (1)
additional dysmorphic features or congenital anomalies were
present and/or (2) there was significant developmental delay
or intellectual disability on neuropsychological assessment; in
addition (3) families including affected first degree relatives
were classified as syndromic, although affected individuals in
those families may have presented with nonsyndromic clinical
features.
Resequencing, bioinformatics, variant validation, and
dosage analysis
Variant screening was performed by next-generation sequen-
cing (NGS)-based resequencing of polymerase chain reaction
(PCR) products encompassing the coding regions and intron/
exon boundaries of the four exons of SMAD6 (NC_000015.10
[chr15:66702110–66782849, hg38]; NM_005585, ENST00000
288840.9). Primer sequences are given in Table S1 and
detailed methods are provided in Supplementary Information.
Variant calls and coverage information were obtained using
the bioinformatic tool amplimap.22
Validation and segregation analysis of variants was under-
taken by dideoxy-sequencing of PCR products from genomic
DNA. The rs1884302 BMP2 polymorphism was genotyped in
all the SMAD6-positive individuals by PCR (Table S1)
followed by EcoRI digest and/or dideoxy-sequencing.
Analysis of SMAD6 dosage using multiplex ligation-
dependent probe amplification (MLPA) is described in the
Supplementary Information.
Frequency- and deleteriousness-based variant stratification
Using the frequency-based filtering framework provided by
Whiffin et al.,23 we estimated the maximum credible
population allele frequency (AF) for any causative variant in
CRS to be 0.000045, assuming a penetrance of 0.2
(Supplementary Information). For each identified variant we
assigned AFmax, the greater of (1) the maximum observed AF
in any population in gnomAD21 (except Other; gnomAD
v2.1.1), where this was based on the presence of ≥2 mutant
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alleles in that population, or (2) the overall AF. We classified
rare alleles as those for which AFmax was <0.000045.
To measure the deleteriousness of the identified variants,
the deleterious score (DS, range 0–6) was calculated based on
exceeding a defined threshold for six separate scores
generated by Annovar24 (Supplementary Information).25 For
comparison, the CADD score was additionally calculated for
missense variants.26
For all SMAD6 variants listed in previous publications4,10–18
and implied to be pathogenic, nomenclature was verified
using Mutalyzer27 and their presence and AF checked in
gnomAD. We calculated the DS and CADD score for all
missense variants.
Functional analysis
Source plasmids and methods used to evaluate the 5′
untranslated region (UTR), splice-site, and missense variants
are provided in the Supplementary Information. Luciferase
measurements and immunoblot quantifications were per-
formed from at least three independent experiments.
Statistical analysis is described in the Supplementary
Information.
RESULTS
Resequencing of SMAD6 in 795 patients with CRS of
unknown etiology
To investigate the contribution of SMAD6 variants in CRS,
we performed NGS-based resequencing of SMAD6 in 795
unsolved patients with any type of CRS. After applying the
joint criteria that variants should be both rare (AFmax <
0.000045) and damaging (predicted loss-of-function [LoF]
and/or DS ≥ 4/6), we identified 18 probands (and 2
additional affected siblings) with heterozygous rare dama-
ging SMAD6 variants (Table 1, Fig. 1, Fig. S1, Table S2).
These SMAD6-positive individuals accounted for 2.3% of
the cohort (3.4% and 2.0% of those classified as syndromic
and nonsyndromic, respectively). Nine probands had LoF
variants, representing a ~18.3-fold enrichment compared
with gnomAD genome sequencing data (9 LoF in minimum
29,066 alleles; P < 10−7, Fisher’s exact test). The highest
prevalence of novel/rare damaging SMAD6 variants
occurred in MS (12/207; 5.8%). Such SMAD6 variants
were much less frequent in isolated SS (3/316; 0.95%) or
other types of suture fusion, but we noted three probands
with coronal suture involvement (one each sagittal+
bicoronal, sagittal+ unicoronal, and unicoronal
synostosis). The varied craniofacial presentation of indivi-
duals with CRS heterozygous for SMAD6 variants is
illustrated in Fig. 2a–c.
Together, these observations confirm the enrichment of
rare, damaging SMAD6 variants in CRS, as reported in
nonsyndromic midline synostosis.4,18 However, this work
extends the previous findings to include syndromic as well as
nonsyndromic patients, and synostosis of coronal sutures.
Among the pure midline synostoses, MS was 6.1-fold more
frequent than SS (P= 0.002, two-tailed Fisher’s exact test).
Phenotypic characterization of SMAD6-positive individuals
Combining these unbiased findings with eight additional
independently identified (see Supplementary Information)
SMAD6-positive CRS patients (three MS, three SS, one
sagittal+ bicoronal and one unicoronal synostosis; Fig. S2),
in total we identified 25 different damaging variants in
SMAD6 (Fig. 1, Table S2) in 28 affected individuals from 26
unrelated families with CRS.
The phenotypes identified in each of the 28 SMAD6-
positive individuals are summarized in Table S3. Of 8 patients
considered to have a syndromic clinical presentation, 1
(subject 5944) was excluded from further consideration owing
to confounding by two additional DNMs likely to contribute
to the phenotype, which had been separately identified by
exome sequencing.28 Of the remaining seven syndromic
subjects, five had congenital heart defects (comprising
atrioventricular septal defect, atrial septal defect [ASD] with
patent foramen ovale, two ASD with ventricular septal defect,
and bicuspid aortic valve with right bundle branch block; only
the first of these required corrective surgery), three had brain
anomalies (comprising ventriculomegaly and absent corpus
callosum, macrocephaly, and mild microcephaly), and one
had duodenal atresia. Seven children had delayed
Table 1 Subjects with CRS analyzed for rare, deleterious SMAD6 variants by NGS-based resequencing.
Nonsyndromic Syndromic Combined
Total SMAD6 positive Total SMAD6 positive Total SMAD6 positive
Metopic 167 9 40 3b 207 12 (5.80%)
Sagittal 279 2a 37 1b 316 3 (0.95%)
Unilateral coronal 150 1 16 0 166 1 (0.60%)
Bilateral coronal 11 0 11 0 22 0
Uni- or bilateral lambdoid 7 0 3 0 10 0
Multisuture 35 1 29 1 64 2 (3.13%)
Sutures not specified 0 0 10 0 10 0
Combined 649 13 146 5 795 18 (2.26%)
CRS craniosynostosis, NGS next-generation sequencing.
aIn one patient, additional bicoronal suture fusion was noted at the time of surgery.
bIncludes proband classified as syndromic because a sibling had sagittal synostosis.
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developmental/intellectual or educational attainment, classi-
fied as mild–moderate in one case and mild in the remainder.
Both congenital heart defects10–12 and neurodevelopmental
disability16 were previously described as significantly asso-
ciated with SMAD6 variants.
Although the craniofacial surgical course for most
patients with CRS was good, four individuals (plus the
child with additional confounding DNMs) were documen-
ted to have raised intracranial pressure (ICP). Of those four,
one with syndromic SS developed additional bilateral
coronal suture fusion and was found to have primary raised
ICP and the other three (two SS, one MS) had raised ICP
following reconstructive craniofacial surgery, necessitating a
second major surgical procedure. Secondarily raised ICP
represents an infrequent complication of simple synostosis
of midline sutures, for example only 2 of 128 patients with
SS,29 and 6 of 202 patients with MS30 who underwent major
calvarial remodeling procedures developed secondarily
raised ICP. The difference from background is significant
(P= 0.042, Fisher’s exact test), suggesting that this is a
complication that should be monitored for in SMAD6-
positive CRS.
Mutational spectrum of SMAD6 and functional evaluation
of the variants
The human SMAD6 protein comprises 496 amino acids and
includes two highly conserved domains (MH1 and MH2),
with MH2 being necessary and sufficient for its inhibitory
activity on TGFβ/BMP signaling.31,32 The 25 different rare
damaging variants in SMAD6 include 12 LoF (seven
frameshift, three stop-gain, two splice-site), one within the
5′ UTR (creating an out-of-frame upstream ATG), an in-
frame duplication (within the MH1 domain) and 11
missense variants (Fig. 1). Ten of the 11 identified missense
variants are clustered in the MH1/MH2 domains and the
remaining substitution is a de novo p.W14R located near
the N-terminus and affecting a highly conserved region of
the inhibitory SMADs (SMAD6/SMAD7; Fig. 1). We
performed in vitro studies of the SMAD6 variants (exclud-
ing the frameshifts and stop-gains) to gather additional
evidence for pathogenicity.
The two splice-site variants (c.817G>C and c.817+2T>A)
are predicted to affect recognition of the intron 1 splice
donor; in both cases, analysis of messenger RNA (mRNA)
extracted from patient cells showed abnormal splice product
(s), absent in the control (Fig. S3). Dideoxy-sequencing
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Fig. 1 Human SMAD6 gene and protein showing variants identified in craniosynostosis (CRS). Top, SMAD6 comprises four exons; positions of
variants affecting translation initiation or splicing are indicated. Middle, cartoon of encoded protein showing conserved domains (MH1 and MH2, including
highly conserved L3 region) and PY and PLDLS motifs.9 Colored shading indicates the position of the MH1 (transparent purple) and MH2 (transparent
orange) domains according to Uniprot, Pfam, and CDD resources, with darker shading denoting overlapping domain assignments. Novel or rare (AFmax <
0.000045) variants identified in CRS patients that are also predicted damaging (loss-of-function [LoF], plus missense variants with DS25 ≥ 4) are indicated
above the cartoon, whereas below in gray are additional missense variants predicted to have lower pathogenicity (DS ≤ 3 and/or AFmax > 0.000045);
negative and positive controls10 used in the functional assays are colored green and blue, respectively. Frameshifts and stop-gain variants are shown with
filled and empty arrowheads, respectively; § = de novo variants; * = novel/rare damaging variants found in addition to the CRS cohort screen; # = AFmax ≥
0.000045 in gnomAD. Bottom, conservation profiles40 of inhibitory SMADs SMAD6 (black), SMAD7 (gray), and all SMAD members (SMAD1–8) combined
(purple line). AF allele frequency, DS deleterious score.
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demonstrated activation of cryptic donor splice sites within
intron 1, resulting in partial intron retention and generating
a frameshift and premature stop codon (Fig. S3).
The 5′ UTR variant (c.-9G>T), present in both affected
individuals of family M130 and assumed to have been
inherited from their father (Fig. S1), creates an out-of-frame
upstream ATG codon with potential initiation activity. Using
a dual-luciferase reporter construct in C2C12 cells, the
translation efficiency of the main open reading frame (ORF)
was reduced, an effect not observed when the c.-9G>A SNP
(rs559095945; AF[total]=0.0001706), affecting the same
nucleotide but not generating an ATG codon, was tested
(Fig. S4).
The inhibitory activity of the SMAD6 missense variants
on BMP signaling was evaluated using a BRE-luc
transcriptional reporter containing a BMP-responsive
element.10,33,34 In addition to the 11 damaging and rare
missense variants summarized in Table S2, we included 10
other missense variants that were either previously
reported as positive (p.C484F) or negative (p.A325T)
controls,10 or that we had encountered during resequen-
cing (Table S2) but were classed as being of uncertain
pathogenicity because they failed one or both criteria of
being damaging and rare (Supplementary Information).
SMAD6 missense variants located outside the MH2
domain maintained potent inhibitory activity, similar to
the wild type (WT) and the p.A325T negative control
(Fig. 3a). For SMAD6 variants located within the MH2
domain, the rare damaging variants associated with CRS
(p.G365C, p.G390R, p.G473R, and p.E489K) showed
reduced inhibitory capacity (statistically significant except
for p.G365C), whereas more frequent and/or less dama-
ging variants (p.S333T, p.K395R) did not. We found a
stronger defect in variants within, or near to, the L3 loop
motif, indispensable for the receptor association (Figs. 1
and 3a);9,35 the strongest defect was present for the p.
G433fs construct, used as an additional control.
To test the stability of mutant SMAD6 proteins, we
performed western blot analysis of the protein lysates
generated for the BRE-luc reporter assay. Strikingly, all 11
CRS-associated rare damaging missense variants (and, in
addition, a 5–amino acid in-frame duplication affecting the
MH1 domain, and the C-terminal frameshift p.G433fs)
exhibited significantly reduced SMAD6 protein levels, sug-
gesting that the substitutions caused protein instability
(Fig. 3b, red and pink bars). With the exception of p.
E171K, average protein levels were <60% of WT. Conversely,
no major instability was observed for eight other novel/rare
variants predicted to have lower pathogenicity, or in more
frequent (AFmax ≥ 0.000045) variants (Fig. 3b, gray bars). As
an additional control we generated WT revertants of plasmids
encoding three of the missense substitutions classified as
pathogenic, and found that the revertant proteins were stable
(Fig. S5).
Collectively, aside from the ten frameshifts/stop-gains
(likely LoF alleles), we provide compelling functional
evidence to support the pathogenicity of all 15 other CRS-
associated rare and predicted damaging variants. The
damaging missense variants mainly cluster in the MH1/
MH2 domains of SMAD6 and significantly affect its activity
and/or stability. We observed a strong negative correlation
between the predicted deleteriousness of each missense
variant and observed protein stability, with the DS (Spear-
man r=−0.67) (Fig. 3c) and CADD (Spearman r=−0.66)
scores performing similarly (Fig. S6).
a
b
c
Fig. 2 Preoperative clinical presentations of craniosynostosis (CRS)
in association with pathogenic heterozygous SMAD6 variants.
(a) Subject 8260 aged 4 months with metopic synostosis, the most fre-
quently associated CRS phenotype, showing hypotelorism (front view) and
trigonocephaly (top view). Newly described clinical presentations include
sagittal and bicoronal synostosis (b, subject 3711 aged 11 months, note
narrow, saddle-shaped skull with frontal bossing) and right unicoronal
synostosis (c, subject 4370 aged 10 months, note facial asymmetry and
recessed brow on right).
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Re-evaluation of SMAD6 variants previously reported as
pathogenic
An enrichment of SMAD6 variants considered to be
pathogenic has been reported in several pathologies distinct
from CRS.10–17 Using our variant categorization (based on AF
and DS), we evaluated all SMAD6 variants that were
previously reported as pathogenic. Systematic review identi-
fied 74 different SMAD6 variants, including 30 missense
(Table S4, Fig. S7). Four of the 74 variants (including 3
missense) have an AFmax ≥ 0.000045; the in-frame deletion
c.79_84del (p.S27_G28del, AFmax= 0.0007) is particularly
frequent. This variant was identified in our initial resequen-
cing (Table S2) but was excluded based on frequency and
occurrence in a poorly conserved region outside the
functional domains. Approximately one third of the pre-
viously reported SMAD6 missense variants are predicted to
have a low (≤3) DS (Table S4, Fig. S8), affecting residues with
low evolutionary conservation (Fig. S9).
Genotyping of BMP2 polymorphism (rs1884302) in SMAD6-
positive individuals
Although 3 of the CRS-associated SMAD6 variants arose de
novo, in 20 cases, the variant was transmitted from a clinically
unaffected parent (11 mothers, 9 fathers); in 3 further cases, 1
or both parents were not available. The SMAD6-transmitting
parents had a total of 23 children unaffected by CRS; taking
account of the two affected sib pairs in the cohort, this
indicates a sib recurrence risk of 2/25= 8%, equivalent to an
estimated penetrance for CRS of SMAD6 variants of ~16%
assuming a 50% transmission rate of the parental SMAD6
variant (unaffected offspring were not genotyped).
To compare our results with the previous work of
Timberlake et al.,4,18 which proposed that the rs1884302
SNP influenced the phenotype associated with SMAD6
variants, we genotyped rs1884302 in all SMAD6-positive
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Fig. 3 Functional analysis of SMAD6 variants. (a) Luciferase assay. The
cartoon at top shows a simplified representation of the BMP signaling
pathway, indicating in red the components transfected into C2C12 cells to
perform the assay. Firefly luciferase activity of the BRE-luc transcriptional
reporter induced by constitutively active BMPR1A (BMPR1A c.a.) was used
to monitor the inhibitory effects of SMAD6 variants on BMP signaling,
similar to previously described.10 Below, graphs represent means ± SEM
from three independent experiments. Data were normalized (using Renilla
levels), relativized to the wild type (WT) and analyzed by one-way analysis of
variance (ANOVA) with Dunnett’s multiple-comparisons test; ∗P ≤ 0.05,
∗∗
P ≤ 0.01, and ∗∗∗P ≤ 0.001. Color-coding of SMAD6 variants follows the
same scheme as in Fig. 1. (b) Analysis of SMAD6 protein stability. Above are
representative examples of western blots (using aliquots of protein extracts
from the luciferase assays), showing SMAD6 protein levels (detected with
anti-FLAG) compared with anti-GAPDH loading control. Control missense
variants (negative, green bar, p.A325T; positive, blue bar, p.C484F) were
selected as previously described.10 Data were normalized (using GAPDH)
and relativized to the WT. The bars represent means ± SEM from three
independent experiments, analyzed and visualized as in (a). (c) SMAD6
average protein levels of 21 different missense variants (from b) plotted
against respective deleterious score (DS).
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individuals. However, we did not observe any association in
our data between presence of the BMP2 risk allele
(rs1884302C) and manifestation with CRS, whether the data
were analyzed in a 2×2 association (Table 2) or by
transmission disequilibrium test (in the 20 families with a
SMAD6 carrier parent, parents heterozygous for the
rs1884302 SNP transmitted 12 C and 7 T alleles to their
affected offspring; P= 0.25, χ2 test). Merger of our 2×2
association data with the previous results of Timberlake
et al.18 did however show a significant association (P= 0.002,
Fisher’s exact test), although this was much weaker than
observed in the original publication (Table 2).
DISCUSSION
This study builds upon the observations of Timberlake
et al.4,18 to obtain a more comprehensive picture of
the significance and impact of SMAD6 variants in CRS. We
identified 28 affected individuals from 26 different families,
adding to the 22 affected individuals from 18 families
previously reported.18 By surveying all types of CRS without
a genetic diagnosis, we gained a broader picture of the range
of CRS phenotypes with which SMAD6 variants may be
associated. We find that MS is most highly represented; 5.8%
of patients with this diagnosis (Fig. 2a) had a rare, damaging
SMAD6 variant, by far the largest monogenic contribution to
MS yet identified.2 SMAD6 variants were less commonly
associated with other types of suture fusion, in particular
variants were significantly less frequent in SS (0.95% of cases
overall) than in MS. We observed four SMAD6-positive
patients in whom fusion of one or both coronal sutures
accompanied the SS, as well as two patients with isolated
unicoronal synostosis (Fig. 2b, c). Although based on small
numbers, the observation that three subjects developed raised
ICP following their primary surgical procedure suggests that
long-term postoperative follow-up of these patients is
important for optimal management. Given the inhibitory
action of SMAD6 on TGFβ/BMP signaling, this work adds
further evidence that overactivity of these pathway(s)
predispose to craniosynostosis.1
Overall, we believe that the data presented here support
adoption of SMAD6 genetic testing to inform genetic
diagnosis of CRS: in the 13-year Oxford birth cohort study,2
10 of 677 (1.5%) individuals harbor rare, damaging SMAD6
variants, making SMAD6 the fifth most common gene for
which variants are found in CRS within this cohort. The
pattern of variants identified in patients with CRS (enrich-
ment for heterozygous LoF, plus damaging missense),
supports a haploinsufficiency mechanism of pathogenesis,
predicting that partial or complete heterozygous deletions of
SMAD6 would also be pathogenic. We screened for such
lesions both experimentally (MLPA in 127 individuals with
MS) and bioinformatically (113 individuals from 98 families
with CRS), but did not detect any deletions in these samples
or data sets (Supplementary Information).
The additional observation by Timberlake et al. that the
genotype at the rs1884302 SNP appeared strongly related to
manifestation of CRS in SMAD6-positive individuals4,18 has
attracted attention as a potential example of digenic or two-
locus inheritance.36 However, our own data do not support
any major modifying role for this SNP (Table 2). Although
upon merger with the previous data the overall effect remains
significant (Table 2), we note that, given the frequency of the
risk allele (C) of ~0.33 (gnomAD, European non-Finnish), the
signal in these previous data4,18 was largely driven by strong
underrepresentation of the C allele in nonpenetrant indivi-
duals, with only weak overrepresentation of C in penetrant
individuals. This pattern runs counter to population genetic
expectations, given the very low penetrance of CRS in
individuals heterozygous for pathogenic SMAD6 variants
(formally estimated as 0.16 from the number of additional
affected and unaffected offspring born to carrier parents).
Furthermore we note that the rs1884302 SNP was originally
investigated because it showed the strongest relationship with
nonsyndromic SS in a GWAS,19 but more recent data for MS
reveal no equivalent association for this SNP.37 Given that the
majority of individuals with deleterious SMAD6 variants have
MS, it is perhaps unsurprising that we did not find an overall
interaction between SMAD6 variants and rs1884302 genotype.
Whether such a relationship might exist for the SMAD6-
positive SS, and whether this interaction could be synergistic
or simply represent an additive effect of the GWAS signal, will
require a much larger sample size to answer. In conclusion,
we caution that the modifying effect of rs1884302 on CRS
phenotype in SMAD6 heterozygotes is unlikely to have useful
predictive clinical application.
Despite the compelling statistical relationship between rare,
damaging SMAD6 variation and CRS, many aspects of
SMAD6 disease pathogenesis remain mysterious, a situation
that poses substantial challenges for genetic counseling.
Notably, although the spectrum of associated pathogenic
variants shows the classical pattern of haploinsufficiency, the
gnomAD pLI (probability of loss-of-function intolerance)
value for SMAD6 is zero, as the number of LoF variants
observed (23) exceeds expectation (11.7).21 Our own data
support that many individuals carrying SMAD6 pathogenic
Table 2 Risk of craniosynostosis in SMAD6 variant carriers in
the presence/absence of the BMP2 risk allele (C).
SMAD6 / BMP2
genotypes
CRS (+) CRS (-) Fisher’s exact P
value (one-tailed)
This work SMAD6 (+) /
BMP2 risk
allele (+)
17 12
SMAD6 (+) /
BMP2 risk allele (-)
11 8 0.60
Timberlake
et al.4,18
SMAD6 (+) /
BMP2 risk
allele (+)
15 1
SMAD6 (+) /
BMP2 risk allele (-)
6 19 0.000011
Combined SMAD6 (+) /
BMP2 risk
allele (+)
32 13
SMAD6 (+) /
BMP2 risk allele (-)
17 27 0.0019
CRS craniosynostosis.
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variants remain asymptomatic, yet a minority are associated
with significant morbidity. Besides the CRS by which these
patients were ascertained, in eight cases syndromes were
diagnosed based on concurrent congenital cardiac and/or
significant neurodevelopmental disorders, features that have
been shown to be associated with SMAD6 variants in
independent studies.10–12,16
Substantial further work will be required to delineate the
overall contribution of SMAD6 variants to multisystem
pathogenesis, and to understand the causal mechanisms
underlying the extreme variability in expressivity and the
unpredictable penetrance. In this regard, for optimum
practice it will be essential carefully to evaluate the pathogenic
contribution of every SMAD6 variant encountered, because it
is evident that there are many SMAD6 variants of inter-
mediate rarity that may be found in mutational screens and
assumed to be pathogenic, when this conclusion could be
incorrect. Here, we show that in our CRS cohort, by applying
joint thresholds for high predicted deleteriousness (DS ≥ 4)
and low allele frequency (AFmax < 0.000045), we could
successfully discriminate missense variants that demonstrated
objective evidence of abnormal protein function in assays,
based on overall stability (Fig. 3b, c) and (for those located in
the MH2 domain), failure to suppress BMP-mediated
signaling (Fig. 3a). In our analysis of previously reported
missense variants implied to be pathogenic, 10/29 did not
meet these joint criteria (Table S4). Such SMAD6 variants
should be prioritized for further functional analysis to enable
their clinical significance to be determined robustly, using
logic similar to that recently described for CFTR variants.38
In determining the clinical utility of SMAD6 genetic testing,
prior reports that subjects with BAV and ascending TAA are
enriched for SMAD6 variation are particularly important,
because these are occult cardiovascular disorders associated
with severe age-related complications, potentially amenable to
targeted echocardiographic screening and intervention. At
present, however, the absolute and age-related risks of these
disorders when association with SMAD6 variants are
unknown. For families within the UK, we have started to
offer echocardiographic screening to asymptomatic SMAD6-
positive parents of children with CRS. Of the seven parents
screened to date, none has shown evidence of either BAV or
TAA, but unexpectedly, one had severe primary pulmonary
hypertension (PPH). While this is not a described association
of SMAD6 variants,39 two of the major known monogenic
predispositions to PPH (variants in BMPR2 and SMAD9) also
involve components of the BMP signaling pathway, so a
pathogenic link to SMAD6 is plausible. These observations
should motivate further efforts to disentangle the complex
role of SMAD6 variation in multiple diseases.
SUPPLEMENTARY INFORMATION
The online version of this article (https://doi.org/10.1038/s41436-
020-0817-2) contains supplementary material, which is available
to authorized users.
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